Over 10 years we help companies reach their financial and branding goals. Engitech is a values-driven technology agency dedicated.

Gallery

Contacts

411 University St, Seattle, USA

+1 -800-456-478-23

// KEY PLATFORM CHARACTERISTICS

Programming Myeloid Cells In Vivo with Novel CAR Technology 

We are powering immunity through in vivo myeloid-programming.

Programming Myeloid Cells In Vivo with Novel CAR Technology  

  • Myeloid optimized mRNA
  • Clinically-validated LNP
  • In vivo validation

Cell Selectivity & Anti-Tumor Activity from Novel Fcα CAR 

  • Potent anti-tumor Fcα pathway 
  • FcRγc expressed only in target cells 
  • Does not require tissue-specific delivery 

Versatile Platform

  • Broadly applicable 
  • Validated targets  
  • Cell-specific expression 
  • Confirmed activity in NHP 
  • Proprietary manufacturing 
  • IND filing H1 2023 

 

// MYELOID PROGRAMMING

Lorem Ipsum Docet

Myeloid cells are a primary orchestrator of immune response and accumulate naturally within solid tumors, in some cases representing up to seventy-five percent of the tumor mass. Myeloid’s adaptations of mRNA for the myeloid compartment have enabled delivery of these receptors directly to the patient without any ex-vivo cell engineering.